We performed a single-center retrospective analysis evaluating clinical outcomes of a cohort of 178 patients with EGFR-mutant lung adenocarcinoma (LUAD) post-EGFR TKI systemic therapy in patients who were treated at MD Anderson Cancer Center. The gene discussed is EGFR; the disease is lung adenocarcinoma.